After Market Movers: ANIK, SLRC, PEGA, ZAGG

Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) are up 17.3%, positioning for a new 52-week high of $40.99 if the gains should hold into Wednesday. The stock just came off an evening-session halt after the company said it received FDA marketing approval for MONOVISC, a single injection supplement to synovial fluid of the osteoarthritic joint, used to treat pain and improve joint mobility in patients suffering from osteoarthritis (OA) of the knee. MONOVISC is the first FDA approved single injection product with HA from a non-animal source.

Solar Capital Ltd. (NASDAQ:SLRC) was higher in late Tuesday trading after the closed-end investment company investing in mid-market firms reported Q4 earnings of $28.9 million, or $0.65 per share, topping analyst estimates looking for just $0.41 per share. Net investment income for the quarter was $18.5 million. Net asset value at the end of the quarter on Dec. 31, 2013, was $22.50 per share, up 1.1% over the end of the prior quarter. SLRC shares were up 2% in tonight’s after-market at $22.50 each, adding 45 cents from Tuesday’s closing price.

Business software firm Pegasystems Inc. (NASDAQ:PEGA) is steady after hours Tuesday after issuing mixed Q4 results, and 2014 guidance that’s above the Street view. PEGA said Q4 income was $23.99 million or $0.61 per share, down from $25.19 million or $0.65 per share a year earlier. The analyst consensus on Capital IQ was for $0.47, but may not be comparable. Revenue of $155.58 million was up from $143.83 million a year earlier. The Cap IQ figure was for $158 million. For 2014, the company guides for non-GAAP revenue of $580 million and EPS of $1.56. The Cap IQ figure is for $573 million in revenue on earnings of $1.48 per share.

Shares of ZAGG Inc. (NASDAQ:ZAGG) are up 15.3% at $4.91 after-hours as the mobile device accessories maker reports better-than-expected Q4 results, FY revenues above analyst consensus, and a board-approved share repurchase. ZAGG reports pro forma EPS of $0.23, compared to $0.37 in Q4 2012. Net sales for the quarter were $66.8 million, compared to $87.5 million reported a year ago. Analysts polled by Capital IQ were expecting EPS of $0.20 on revenues of $61.3 million. For 2014, issued net sales guidance in a range of $218 million-$228 million vs. analyst consensus of $214 million. ZAGG separately said its board has authorized a $10 million share repurchase. The company paid off the balance on the Line of Credit during Q1 2014, and will use cash from operations to fund the share repurchase in 2014.


Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone